Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver DiseaseBusiness Wire • 07/29/21
Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other IndicationsSeeking Alpha • 07/06/21
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell CarcinomaBusiness Wire • 07/06/21
Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal ModelsBenzinga • 07/02/21
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed DyslipidemiaBusiness Wire • 06/30/21
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver CongressBusiness Wire • 06/26/21
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research CongressBusiness Wire • 06/25/21
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver CongressBusiness Wire • 06/23/21
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled GoutBusiness Wire • 06/21/21
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe HypertriglyceridemiaBusiness Wire • 06/03/21
Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21